证券代码：688136 证券简称：科兴制药 公告编号：2025-070 科兴生物制药股份有限公司 2025 年第一次临时股东会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东会召开的时间：2025 年 08 月 29 日 （二） 股东会召开的地点：深圳市南山区高新中一道与科技中一路交汇处创益 科技大厦 B 栋 19 楼会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 84 | | --- | --- | | 普通股股东人数 | 84 | | 2、出席会议的股东所持有的表决权数量 | 121,857,761 | | 普通股股东所持有表决权数量 | 121,857,761 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比例（%） | 61.5110 | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 61.511 ...

北京市嘉源律师事务所 关于科兴生物制药股份有限公司 2025年第一次临时股东大会的 法律意见书 西城区复兴门内大街 158 号远洋大厦 4 楼 中国·北京 滤律师事务所 A YUAN LAW OFFICES 北京 BEI JING·上海 SHANGHAI·深圳 SHENZHEN·香港 HONG KONG·广州 GUANGZHOU·西安 XI'AN 致:科兴生物制药股份有限公司 北京市嘉源律师事务所 关于科兴生物制药股份有限公司 2025年第一次临时股东大会的 法律意见书 嘉源(2025)-04-615 北京市嘉源律师事务所(以下简称"本所")接受科兴生物制药股份有限公 司(以下简称"公司")的委托,根据《中华人民共和国公司法》(以下简称"《公 司法》")《上市公司股东会规则》(以下简称"《股东会规则》")等现行有 效的法律、行政法规、部门规章、规范性文件(以下简称"法律法规")以及《科 兴生物制药股份有限公司章程》(以下简称"《公司章程》")的有关规定,指 派本所律师对公司2025年第一次临时股东大会(以下简称"本次股东大会")进 行见证,并依法出具本法律意见书。 为出具本法律意见书,本所指派律师现场见证了本 ...

证券代码：688136 证券简称：科兴制药 公告编号：2025-071 科兴生物制药股份有限公司 关于完成董事会换届选举及 聘任高级管理人员、证券事务代表、审计监察部负责人的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 科兴生物制药股份有限公司（以下简称"公司"）于2025年8月29日分别召 开职工代表大会、2025年第一次临时股东会，选举产生了公司第三届董事会，任 期自2025年第一次临时股东会审议通过之日起三年。 （二）董事长及董事会专门委员会委员选举情况 2025 年 8 月 29 日，公司召开第三届董事会第一次会议，全体董事一致同意 选举邓学勤先生为公司第三届董事会董事长，并选举产生了公司第三届董事会战 略委员会、审计委员会、提名委员会、薪酬与考核委员会委员，具体情况如下： | 专门委员会 | 委员 | | 召集人 | | --- | --- | --- | --- | | 战略委员会 HE | RUYI、方俊辉、赵彦轻、崔宁 | HE RUYI | | | 审计委员会 | 张汉斌、方俊辉、黄凯昆 | 张汉 ...

证券代码：688136 证券简称：科兴制药 公告编号：2025-069 科兴生物制药股份有限公司 关于选举第三届董事会职工代表董事的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 科兴生物制药股份有限公司（以下简称"公司"）第二届董事会任期已届满， 根据《中华人民共和国公司法》（以下简称"《公司法》"）《上海证券交易所 科创板股票上市规则》《上海证券交易所科创板上市公司自律监管指引第 1 号— —规范运作》等法律法规、规范性文件的规定，公司于 2025 年 8 月 29 日召开 2025 年第一次临时股东会，审议通过了《关于取消监事会、变更注册资本暨修 订 <公司章程>的议案》等议案。根据修订后的《科兴生物制药股份有限公司章 程》（下称《公司章程》）规定，公司第三届董事会将由 4 名非独立董事、3 名 独立董事和 1 名职工董事组成，其中 1 名职工董事由职工代表大会选举产生。 公司于 2025 年 8 月 29 日召开职工代表大会，审议通过了《关于选举公司第 三届董事会职工代表董事的议案》，同意选举黄凯昆先生（简历 ...

Group 1 - The company, Sinovac Biotech, is planning to issue overseas listed shares (H-shares) and list on the Hong Kong Stock Exchange to enhance its international business development and competitiveness [1] - The H-share listing requires approval from the company's board, shareholders, and various regulatory bodies, indicating uncertainty in the process [1] - The company aims to leverage international capital market resources to optimize its capital structure and diversify financing channels [1] Group 2 - Sinovac Biotech's major shareholder, Shenzhen Keyi Pharmaceutical Holdings, plans to transfer 6,037,717 shares, representing 3.00% of the total share capital, due to funding needs [2] - The transfer price is set at 36.70 yuan per share, totaling approximately 221.58 million yuan [2] - Following the transfer, the shareholding of Keyi Pharmaceutical and its associated parties will decrease from 63.89% to 60.38% [2] Group 3 - Keyi Pharmaceutical previously reduced its holdings by 5,989,200 shares, or 3.00% of the total share capital, between June 26 and July 9, 2025, with a total amount of approximately 220.99 million yuan [3] - Over the past two months, Sinovac Biotech has realized approximately 443 million yuan from these transactions [4] - The company was listed on the Shanghai Stock Exchange on December 14, 2020, raising a total of 1.11 billion yuan, with a net amount of 999.5 million yuan after expenses [4][5]

Group 1 - The weight loss drug concept stocks experienced a decline in the afternoon trading session on August 28, with Meinuohua hitting the daily limit down [1] - MediXy and Kangyuan Pharmaceutical both fell over 7%, indicating a significant drop in their stock prices [1] - Other companies such as Kexing Pharmaceutical and Haixiang Pharmaceutical also reported notable declines in their stock performance [1]

Group 1 - The weight loss drug concept stocks are experiencing a decline in the afternoon trading session [1] - Meituan's stock has hit the daily limit down, while Medici and Kangyuan Pharmaceutical have dropped over 7% [1] - Other companies such as Kexing Pharmaceutical and Haixiang Pharmaceutical are also among the top decliners [1]

Group 1 - The "A+H" listing model is gaining momentum, with nearly 20 A-share companies announcing plans to list in Hong Kong since August, indicating a strategic move towards internationalization [1][2] - The new IPO regulations effective from August 4 have provided significant impetus for this trend, allowing for a more flexible allocation mechanism and reducing compliance costs for A-share companies [1][2] - Companies like Greeenme have explicitly stated that their goal for listing in Hong Kong is to enhance their global strategy and improve their international brand image and competitiveness [1][3] Group 2 - Enterprises with large asset scales, high capital expenditures, and mature international operations are becoming the main players in the "A+H" model, utilizing the Hong Kong market for financing to support cross-border mergers and overseas expansions [2] - The "A+H" model is reshaping the valuation system and liquidity structure of Chinese listed companies, with significant foreign capital inflows into Hong Kong stocks, surpassing last year's total by 90% as of mid-2025 [2] - The dual listing structure helps mitigate valuation risks associated with market volatility, as seen with companies like CATL, which attracted substantial international long-term capital post-listing [2][3] Group 3 - There is a noticeable shift in the types of companies pursuing "A+H" listings, with more emerging sectors like renewable materials and biomedicine entering the fray, reflecting a deeper integration of China's tech industry with international capital markets [3] - The continued support from policies and the optimization of related systems are expected to propel the "A+H" model into a new phase of high-quality development, with more competitive Chinese companies likely to pursue this path for global capital and strategic positioning [3] - The maturation of the "A+H" model is a natural outcome of the ongoing deepening of China's capital market openness and a strategic choice for companies to enhance their international competitiveness [3]

Core Viewpoint - The "A+H" listing trend is gaining momentum, with nearly 20 A-share companies announcing plans to list in Hong Kong since August, indicating a strategic move towards internationalization and capital market access [1][2]. Group 1: A+H Listing Trend - Companies like Grinmei, Huqin Technology, and Kexing Pharmaceutical are among those pursuing Hong Kong listings, highlighting the effectiveness of the "A+H" dual-track model for international expansion [1]. - The new IPO regulations effective from August 4 have provided a significant boost to this trend, allowing for more flexible allocation mechanisms and reducing compliance costs for A-share companies [1][2]. Group 2: Characteristics of A+H Companies - Enterprises with large asset scales, high capital expenditures, and mature international operations are leading the "A+H" model, utilizing the Hong Kong market for financing to support cross-border mergers and overseas expansions [2]. - Growth-oriented technology companies are also showing high interest in the "A+H" model, which offers broader capital allocation opportunities [2]. Group 3: Impact on Valuation and Liquidity - The "A+H" model is reshaping the valuation system and liquidity structure of Chinese listed companies, with significant foreign capital inflow observed in the Hong Kong market [2][3]. - For instance, by mid-2025, net inflows through the Hong Kong Stock Connect exceeded 730 billion HKD, surpassing 90% of last year's total [2]. Group 4: Future Outlook - The ongoing policy support and institutional optimization are expected to elevate the "A+H" model into a new phase of high-quality development, with more competitive Chinese companies likely to adopt this path for global capital and strategic positioning [3]. - The maturation of the "A+H" model reflects the deepening of China's capital market opening and the strategic choice of Chinese enterprises to enhance their international competitiveness [3].

Core Viewpoint - The celebration of the sixth Entrepreneur Day in Zhangqiu District highlights the importance of entrepreneurs in driving economic growth and social development, emphasizing a collaborative environment between the government and businesses [1][5]. Group 1: Economic Development - Zhangqiu is currently experiencing a positive economic phase, with a focus on high-quality development and the integration of various industries [1]. - The district has established a "3+2+2" key industrial chain group, focusing on automotive, advanced materials, and specialized equipment as leading industries, with emerging sectors in aerospace information and new-generation information technology [3]. - By the first half of 2025, the output value of the three main industrial chains is expected to account for 77.5% of the total output value in the district [3]. Group 2: Support for Entrepreneurs - The district has released lists of the top 50 private manufacturing enterprises and the top 100 entities in the real economy for 2024, providing various incentives such as health check cards and educational support for the leaders of these companies [1]. - Zhangqiu has implemented a project service guarantee mechanism, enhancing the efficiency of project approvals and land use, which has led to significant improvements in project implementation times [4]. - The government has established a closed-loop mechanism for addressing enterprise demands, ensuring that issues related to project initiation and regulatory compliance are resolved efficiently [3][4]. Group 3: Innovation and Growth - Local enterprises, such as the Shandong Shengquan Group, are focusing on becoming global leaders in bio-manufacturing and advanced materials, aiming for rapid growth through innovation and value chain enhancement [2]. - The district has recognized 52 new provincial innovative small and medium-sized enterprises and 3 smart factories this year, indicating a strong emphasis on technological advancement and innovation [4]. - Companies are encouraged to enhance their competitive edge through continuous technological upgrades and talent development, fostering a conducive environment for business growth [5].